Through a newly formed partnership, BioClinica, a global provider of clinical trial management solutions, will integrate Oxford-based Mirada Medical's XD3 software solution into its imaging core lab technology to enhance its PET capabilities and expertise for molecular imaging trials.
Mirada’s integrated software will provide tools and efficient workflows for the quantification and tracking of findings for major modalities including PET, CT, MR and MR/PET. Once XD2 is integrated into BioClinica’s BioPACS and BioREAD technologies, the imaging workflow and processing programs’ will be capable of helping trial sponsors harness the superior imaging results that are achievable through PET scans and multiple modalities technology.
Through the partnership, BioClinica's PET image processing capabilities will extend oncology clinical trials with support for the following features:
Enhanced capabilities for PERCIST tumor response assessment criteria
Normalization of uptake by body weight, lean body mass or body surface area for SUV measurements
Registration and fusion capabilities between PET, CT and MR
Customizable workflow and user interface to provide flexibility in the independent read design
Furthermore, as part of this partnership, Mirada will present at BioClinica's 2012 User Conference—which is designed to help BioClinica imaging core lab customers and eClinical solution users discover new ways to run faster, more efficient clinical trials.
